Evidence mapPaperPMID 42322365Full record

ReviewMolecular neurobiology2026

IL-4 in Alzheimer's Disease-Mechanisms and Therapeutic Potential.

Guangya Liu, Weixian Li, Jiangmin Chen, Shuyu Xu, Xinyuan Liu, Zijie Wang, Qihui Yang, Anqi Xie, Yanjun Du

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Guangya LiuCollege of Acupuncture-Moxibustion and Orthopaedics, Hubei University of Chinese Medicine, Wuhan, 430061, Hubei, China.
Weixian LiCollege of Acupuncture-Moxibustion and Orthopaedics, Hubei University of Chinese Medicine, Wuhan, 430061, Hubei, China.
Jiangmin ChenCollege of Acupuncture-Moxibustion and Orthopaedics, Hubei University of Chinese Medicine, Wuhan, 430061, Hubei, China.
Shuyu XuCollege of Acupuncture-Moxibustion and Orthopaedics, Hubei University of Chinese Medicine, Wuhan, 430061, Hubei, China.
Xinyuan LiuPathology & Pathophysiology Department, Basic Medicine School, Key Laboratory of Neurological Diseases of Hubei Province and National Education Ministry, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Zijie WangCollege of Acupuncture-Moxibustion and Orthopaedics, Hubei University of Chinese Medicine, Wuhan, 430061, Hubei, China.
Qihui YangCollege of Acupuncture-Moxibustion and Orthopaedics, Hubei University of Chinese Medicine, Wuhan, 430061, Hubei, China.
Anqi XieCollege of Acupuncture-Moxibustion and Orthopaedics, Hubei University of Chinese Medicine, Wuhan, 430061, Hubei, China.
Yanjun DuCollege of Acupuncture-Moxibustion and Orthopaedics, Hubei University of Chinese Medicine, Wuhan, 430061, Hubei, China. yjdu-acu@hbucm.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the pathological hallmarks of amyloid-beta (Aβ) plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein. Neuroinflammation, driven largely by glial cells, is now recognized as a critical player in AD pathogenesis, contributing to both initiation and progression. Recent studies have indicated that interleukin-4 (IL-4), an anti-inflammatory cytokine with powerful immunomodulatory functions, facilitates the resolution of neuroinflammation. However, other research findings suggest that intervention with IL-4 might also exacerbate the course of AD, which complicates the understanding of the role of IL-4 in AD. Hence, this review comprehensively examines the complex and dualistic role of IL-4 in AD. We begin by outlining the contribution of IL-4 to the innate immunity of the brain, including the biological characteristics of IL-4, the main responsive cells in the central nervous system, and the directly activated signaling pathways. Next, we explored the dualistic role of IL-4 in AD from four perspectives: its impact on the clearance of amyloid plaques, its effect on the phosphorylation of the tau protein, its regulation of neuroinflammation, and its effects on neuroprotection. Finally, we summarize the current research status of the use of IL-4 as a therapeutic target to regulate immune function, alleviate neuroinflammation, and improve AD, as well as the future challenges of this approach as a therapeutic strategy for AD.

Indexed as

Alzheimer DiseaseInterleukin-4AnimalsBrainHumansSignal Transductiontau ProteinsInterleukin-4tau ProteinsAlzheimer’s diseaseInterleukin-4Neuroinflammation

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.